Search

U radu se iznose rezultati liječenja nacionalne skupine za dječju hematologiju djece oboljele od akutne limfatičke leukemije u Hrvatskoj u vremenskom periodu od 1.10.1996. do 31.12.2000. godine.Postignuti rezultati liječenja dječjih ALL prema ALL-BFM95 protokolu, gotovo su isti kao i rezultati koji se postižu u vodećim europskim centrima za liječenje djece oboljele od akutne limfatične leukemije.

U radu se iznose rezultati liječenja nacionalne skupine za dječju hematologiju djece oboljele od akutne limfatičke leukemije u Hrvatskoj u vremenskom periodu od 1.10.1996. do 31.12.2000. godine.Postignuti rezultati liječenja dječjih ALL prema ALL-BFM95 protokolu, gotovo su isti kao i rezultati koji se postižu u vodećim europskim centrima za liječenje djece oboljele od akutne limfatične leukemije.

From 1988 to 1998 one hundred forty eight patients with acute lymphoblastic leukemia (ALL) were enrolled into prospective study. The aim of the study was to evaluate efficacy of common treatment for acute lymphoblastic leukemia and to determine risk factor for outcome. Out of 148 patients, 31 (21%) had acute nondifferentiated leukemia (according to the FAB criteria) with expression of lymphoid markers. Those patients were treated in the same way as patients with ALL. According to the type of consolidation therapy patients were divided into three groups. Chemotherapy alone received 38 (38%) patients, and 30 (31%) patients received autologous stem cell transplantation (SCT) or allogeneic STC. There were no statistical difference in sex, age, FAB subtype, number of WBC and platelets in the time of diagnosis and incidence of cytogenetic abnormalities between these three groups. Median follow-up for chemotherapy group was 68 (range 12-98) months, for allogeneic SCT 102 (range 12-120) and for autologous SCT 99 (range 12-105) months. As a condition regimen the majority of patients treated with SCT received total body irradiation followed by cyclophosphamide. There was statistically significant difference in the source of stem cell for transplantation: in 20% of autologous SCT peripheral blood was used as source of stem cells. Relapse rate was significantly higher in patients receiving chemotherapy alone than in patients receiving either autologous or allogeneic SCT (83 vs. 45 vs. 27%, p

Na Zavodu za hematologiju i onkologiju Klinike za pedijatriju Šalata liječeno je 38 djece s akutnom limfatičkom leukemijom protokolom ALL-BFM 95 u periodu od 1.01.1995. do 31.12.1998.godine. Prva kompletna remisija postignuta je u 38 bolesnika (100% -33.dan ; u 32/84% -15.dan). Prvi relaps nastao je u 6 (15% ) bolenika (3 hematološki relaps, 1 meningelani relaps, 2 hematološki i meningealni relaps). 30.06.1999. u prvoj kompletnoj remisiji je i dalje 32 (85%) bolesnika ; 3 (8%) bolesnika je umrlo tijekom relapsa, a 3 je u drugoj remisiji. U grupi standardog rizika u prvoj kompletnij remisiji je 90%, u grupi sredjeg rizika 86%, a u grupi visokog rizika 40% bolesnika. Postignuti preliminarni rezultati potvrđuju vrijednost protokola ALL-BFM 95 u liječenju djece s akutnom limfatičkom leukemijom.